A successful course of antiviral therapy in patients with chronic hepatitis C virus (HCV) infection is durable and can result in significant long-term benefit; however, many patients who undergo combination therapy with pegylated interferon alfa (PegIFN) and ribavirin (RBV) ultimately fail and develop persistent viremia. Our ability to achieve a sustained virologic response (SVR) is especially limited in patients with genotype 1 infection. Additional factors that characterize the most challenging subgroups of treatment candidates include those with advanced fibrosis or cirrhosis, fatty liver disease, increased age, obesity, and African American ethnicity [1] [2] [3] [4] [5] [6] . Based on several large prospective randomized clinical trials, the rates of SVR associated with genotype 1 infection have ranged from 41 to 52% [1] [2] [3] 5] . These studies have demonstrated further reductions in SVR to as low as 35% in genotype 1 patients with a high viral load [2, 3, 5] .
In an effort to increase the potential of achieving an SVR while optimizing adherence to therapy, various strategies have emerged with an emphasis towards an individualized approach. Although some data are conflicting, proposed strategies have included a shortened duration of treatment in subsets of patients with favorable characteristics, including low baseline serum HCV RNA levels and rapid virologic response (RVR) during therapy [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Alternatively, a key strategy applicable to patients with genotype 1 infection is the extension of treatment duration based on the timing of viral clearance, in which patients with a slow virologic response may receive up to 72 weeks of therapy [17] [18] [19] [20] [21] [22] .
Other strategies have involved the use of alternative and potentially more potent forms of interferon-based therapy. Although higher doses of PegIFN and RBV may result in more rapid viral suppression and an increase in SVR, this appears to occur at the cost of decreased tolerability as demonstrated in a recent prospective study [23] . Consensus interferon (CIFN) has emerged as a viable treatment option in both naïve and previously treated patients with chronic HCV, particularly in those with difficult-to-treat characteristics. CIFN is a synthetic type I interferon protein that comprises a consensus sequence of the most common amino acids found in naturally occurring alpha interferon subtypes. Initial in vitro studies suggested that CIFN has superior antiviral efficacy in comparison with interferon alfa (IFN) [24] , while prospective clinical data have reported a significant increase in SVR for genotype 1 patients with high viral load treated with CIFN versus standard IFN [25, 26] . Although comparative data are limited, one study suggests that CIFN may be as effective as PegIFN when used in combination with RBV for the treatment of genotype 1 patients [27] . A long-acting form of CIFN is not available; however, daily dosing may further enhance viral suppression [28] and has been shown to be an effective dosing strategy in a large prospective clinical trial of patients who failed prior PegIFN and RBV therapy [29] .
In this issue of Digestive Diseases and Sciences, Ho and colleagues present their experience with a tailored approach to therapy in a cohort of treatment-naïve genotype 1 patients with difficult-to-treat characteristics, utilizing strategies including extended treatment duration and the use of high-dose daily CIFN (15 mcg) in combination with RBV [30] . This study population of mostly VA patients included a significant proportion with high viral load, advanced fibrosis, and African American ethnicity. Patients were randomized to receive either a 1-year course of daily CIFN and RBV or a variable duration of therapy. In the variable duration arm, an additional 48 weeks of daily CIFN and RBV was administered following achievement of a virologic response within the first 24 weeks, defined as a[2-log reduction or undetectable serum HCV RNA.
As a pilot study emphasizing tolerability and efficacy, the findings reported by Ho et al. [5, 31] are limited by relatively small numbers; however, several key issues should be highlighted. The overall intention to treat SVR based on pooled data from both treatment arms is comparable to reports from studies involving PegIFN and RBV in genotype 1 populations with high viral loads and advanced fibrosis. As expected, achievement of viral clearance early during the course of therapy in this cohort was associated with an increase in SVR; yet extension of treatment duration did not appear to enhance the rate of virologic response in slow responders. As the authors point out, a major factor associated with this observation was the high rate of discontinuation due to adverse events or noncompliance in 50% of patients overall and in 40% within the first 24 weeks of therapy. Consequently, only a minority of patients actually reached completion of an extended course.
Early discontinuation of therapy due to adverse events or noncompliance has been noted in previous prospective studies involving daily dosing of CIFN plus RBV. In one small clinical trial of CIFN 9 mcg daily plus RBV, over one-third of treatment-naïve patients were unable to complete the expected course of therapy [32] . In the DailyDose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) trial, over 20% of treatment-experienced patients who previously failed courses of PegIFN and RBV were reported to discontinue therapy due to adverse events or loss to follow-up (Fig. 1) [29] . Higher doses of CIFN have been associated with an increased likelihood of discontinuation and dose reductions due to adverse events [33] , which may be a contributing factor to the high rate of early discontinuation observed by Ho et al. An additional factor includes the increased proportion of patients with advanced fibrosis. However, the wide variation in discontinuation rates among study sites, as noted by the authors, suggests the presence of external or local factors influencing adherence within this study population. In contrast with daily CIFN and RBV, early discontinuation associated with combination PegIFN and RBV has been reported in the range of 13-16% [1] [2] [3] 5] , although rates may be increased in patients with cirrhosis [31] .
Despite the low overall SVR, a striking finding in this study was the high SVR reported in the small proportion of patients (20%) who maintained adherence with at least 80% of the CIFN dose, 80% of the RBV dose, and 80% of the expected duration of therapy (80/80/80 adherence). The importance of adherence in achieving SVR is well established, particularly in patients with genotype 1 infection. Although direct comparisons were not made, the SVR noted in this minority of patients who were adherent (85%) was greater than what has been reported in adherent genotype 1 patients receiving PegIFN and RBV (51-63%) [34] . Albeit promising, this finding is limited by a small sample size.
Altogether, these results emphasize the impact of adherence on virologic response as well as the challenges encountered with potent antiviral therapy requiring highfrequency dosing regimens. CIFN therapy may indeed result in more successful outcomes in challenging populations, yet virologic response rates may be sacrificed by decreased tolerability associated with the daily administration of higher therapeutic doses. An additional point highlighted by this study is that loss of adherence may result in failure of other strategies, such as extended treatment duration, that would otherwise be utilized in a tailored approach.
Ultimately, larger prospective studies will be required to more accurately determine the role of high-dose daily CIFN and RBV in difficult-to-treat populations. A key factor in optimizing outcomes associated with CIFN may involve the selection of candidates with the greatest likelihood of completing a full course of therapy. In the future, direct acting antiviral agents (DAA) will likely add another dimension to the individualized approach to HCV therapy, in which the duration may be altered significantly based on [30, 32] as well as treatment-experienced patients [29] . Discontinuation occurred for reasons not related to virologic response. Factors resulting in discontinuation shown here include adverse events, noncompliance, and loss to follow up.
a Data only shown from treatment arm receiving combination CIFN and RBV. CIFN consensus interferon, RBV ribavirin early treatment responses [35] [36] [37] . Whether high-dose daily CIFN therapy will emerge as a key player in combination with DAA for specific subsets of challenging patients has yet to be determined; however, adherence will remain a critical factor.
